This trial is testing the safety of Anti-SLAMF7 CAR-T cells in myeloma. The Anti-SLAMF7 CAR-T cells in this trial are altered to include a ‘stop switch’, to help limit toxicity of this therapy.
This trial is currently open and accepting patients.
This Phase 1 trial is being run in two different arms, dose escalation and dose expansion. It is non-randomized, with sequential assignment, which means that the dose you receive, or the trial arm you enroll in, depend on when you join the trial. It is also open label, which means that both the researchers and you will know which dose you are receiving, or arm you are participating in.
ARM 1:
ARM 2:
If patients develop bad side effects from the Anti-SLAMF7, researchers can decide to give them Rimiducid by intravenous infusion to cause cell death of the Anti-SLAMF7 CAR-T cells.
Phase 1
Enrollment: 42 patients (estimated)
View MoreThe following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
December 05, 2019
Dr. Kochenderfer is a physician-scientist working to develop immunotherapies for lymphoma, leukemia, and multiple myeloma. His current work focuses on chimeric antigen receptor T-cell therapies.
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
SparkCures is working closely with National Cancer Institute (NCI) to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors